<?xml version="1.0" encoding="utf-8"?><dg:chunk cp:version="2.15.15.0.1705579614438-233.0" xmlns:docset="http://www.docugami.com/2021/dgml/docugami/MedicalNotes(UNC)" xmlns:addedChunks="http://www.docugami.com/2021/dgml/docugami/MedicalNotes(UNC)/addedChunks" xmlns:dg="http://www.docugami.com/2021/dgml" xmlns:dgc="http://www.docugami.com/2021/dgml/docugami/contracts" xmlns:dgm="http://www.docugami.com/2021/dgml/docugami/medical" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:cp="http://classifyprocess.com/2018/07/"><docset:TimothyPMoranPatientHP14-section><dg:chunk structure="h1">

              <docset:PhysicianName>Timothy P. Moran </docset:PhysicianName><docset:PatientHistoryandPhysical>Patient H&amp;P </docset:PatientHistoryandPhysical>#<docset:PatientHP>14 </docset:PatientHP></dg:chunk><docset:TimothyPMoranPatientHP14 structure="div"><docset:CC-section><dg:chunk structure="h1">

              CC: </dg:chunk><docset:CC structure="div">Bilateral knee pain </docset:CC></docset:CC-section><docset:HPI-section><dg:chunk structure="h1">

              HPI: </dg:chunk><docset:HPI structure="div"><docset:PainCrisis structure="p">

              The patient is a <docset:Age>24 </docset:Age><docset:Age>yo </docset:Age>African-American man with h/o sickle cell disease who presented to the ED with a <docset:PainDuration>2 day </docset:PainDuration>h/o bilateral knee pain. The pain began <dgc:Weekday>Thursday </dgc:Weekday>morning at approx <docset:PainOnsetTime>4:00 am </docset:PainOnsetTime>while the patient was working the night shift at a department store. The pain was described as aching and had a gradual onset. The patient had difficulty sleeping <dgc:Weekday>Thursday </dgc:Weekday>because of the pain. The pain continued to gradually increase in severity to an <docset:PainIntensity>8/10 </docset:PainIntensity>today. The pain was exacerbated with walking or standing and was not significantly relieved with <dgm:Medication>Percocet </dgm:Medication>that the patient had by prescription. The knee pain is unlike any prior episode of pain crisis. The patient reports some <dgm:Condition>chills </dgm:Condition>and mild SOB, but denies fever, N/V, <dgm:Condition>cough</dgm:Condition>, <dgm:Condition>chest pain</dgm:Condition>, abdominal pain or recent <dgm:Condition>trauma </dgm:Condition>to the knees. In the ED, the pain was primarily localized to the right knee and was <dgc:Number>8/10 </dgc:Number>in intensity. The patient was started on NS at <docset:FluidRate>125ml</docset:FluidRate>/hr and received two doses (6mg and 

              8mg) of <dgm:Medication>morphine</dgm:Medication>. </docset:PainCrisis><docset:PMH-section><dg:chunk structure="h1">

              PMH </dg:chunk><docset:MedicalSurgicalHistory-section structure="div"><dg:chunk structure="h1">

              Medical/<docset:SurgicalHistory>Surgical </docset:SurgicalHistory>History: </dg:chunk><docset:MedicalSurgicalHistory structure="ol" style="list-style-type: decimal; boundingBox:{left: 375.0; top: 1441.7; width: 1866.7; height: 466.7; page: 1;}; "><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 1441.7; width: 1708.3; height: 120.8; page: 1;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 1441.7; width: 37.5; height: 62.5; page: 1;}; ">

                  1. </dg:chunk><dg:chunk>Sickle cell disease: Last pain crisis was while living in ------------ over <docset:LastPainCrisis>1 year </docset:LastPainCrisis>ago. Followed by <docset:DoctorName>Dr. Ataga </docset:DoctorName>in Heme clinic at <docset:LastPainCrisis>UNC</docset:LastPainCrisis>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 1558.3; width: 1866.7; height: 233.3; page: 1;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 1558.3; width: 37.5; height: 62.5; page: 1;}; ">

                  2. </dg:chunk><docset:HospitalizationDetails structure="p">Hospitalization at <docset:HospitalizationDetails>Wake Hospital </docset:HospitalizationDetails>in July for <dgm:Condition>chest pain </dgm:Condition>after being hit with basketball, but subsequently developed increased difficulty in breathing and fevers requiring hospitalization for approximately <docset:HospitalizationDuration>one week </docset:HospitalizationDuration>and received <docset:BloodTransfusion>3U </docset:BloodTransfusion>PRBCs. Patient unclear whether he had <dgm:Condition>pneumonia </dgm:Condition>or acute chest <dgm:Condition>syndrome</dgm:Condition>. </docset:HospitalizationDetails></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 1787.5; width: 579.2; height: 62.5; page: 1;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 1787.5; width: 37.5; height: 62.5; page: 1;}; ">

                  3. </dg:chunk><dg:chunk structure="p">h/o of stuttering <dgm:Condition>priapism </dgm:Condition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 1845.8; width: 600.0; height: 62.5; page: 1;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 1845.8; width: 37.5; height: 62.5; page: 1;}; ">

                  4. </dg:chunk><dg:chunk structure="p">h/o lower extremity <dgm:Condition>ulcers </dgm:Condition></dg:chunk></dg:chunk></docset:MedicalSurgicalHistory></docset:MedicalSurgicalHistory-section></docset:PMH-section></docset:HPI></docset:HPI-section></docset:TimothyPMoranPatientHP14></docset:TimothyPMoranPatientHP14-section><docset:FamilyHistory-section><dg:chunk structure="h1">

              Family History: </dg:chunk><docset:FamilyHistory structure="div">

              The patient has <docset:NumberofSiblingswithSickleCellDisease>two </docset:NumberofSiblingswithSickleCellDisease>siblings with sickle cell disease. No family h/o <dgm:Condition>arthritis</dgm:Condition>, <dgm:Condition>heart disease</dgm:Condition>, DM, HTN, liver or kidney disease. </docset:FamilyHistory></docset:FamilyHistory-section><docset:SocialHistory-section><dg:chunk structure="h1">

              <dg:chunk>Social History</dg:chunk>: </dg:chunk><docset:SocialHistory structure="div">

              Patient lives in - with mother and <docset:NumberofSiblings>four </docset:NumberofSiblings>siblings. Patient originally from - but moved to US about <docset:TimeinUS>1.5 years </docset:TimeinUS>ago. Patient works at department store. The patient denies tobacco or IV drug use, but reports occasional EtOH use with last time in <docset:LastEtOHUse>August</docset:LastEtOHUse>. No recent travel or sick contacts. </docset:SocialHistory></docset:SocialHistory-section><docset:AllergiesNKDAMedications-section><dg:chunk structure="h1">

              Allergies: <dg:chunk><docset:AllergiesandMedications>NKDA </docset:AllergiesandMedications>Medications</dg:chunk>: </dg:chunk><docset:AllergiesNKDAMedications structure="ol" style="list-style-type: decimal; boundingBox:{left: 375.0; top: 2708.3; width: 1004.2; height: 116.7; page: 1;}; "><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 2708.3; width: 425.0; height: 62.5; page: 1;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 2708.3; width: 37.5; height: 62.5; page: 1;}; ">

                  1. </dg:chunk><dg:chunk structure="p"><dgm:Medication>folic acid </dgm:Medication>5mg qd </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 375.0; top: 2766.7; width: 1004.2; height: 58.3; page: 1;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375.0; top: 2766.7; width: 37.5; height: 58.3; page: 1;}; ">

                  2. </dg:chunk><dg:chunk><dgm:Medication>Percocet </dgm:Medication>(<docset:Dosage>5/325</docset:Dosage>mg) <docset:Prescription>1 </docset:Prescription>tab <docset:DosageFrequency>q4</docset:DosageFrequency>-<docset:PainMedicationSchedule>6hr </docset:PainMedicationSchedule>PRN for pain </dg:chunk></dg:chunk></docset:AllergiesNKDAMedications></docset:AllergiesNKDAMedications-section><dg:chunk structure="h1">

              Review of Systems: </dg:chunk><dg:chunk><dg:chunk structure="h1">

              Constitutional: </dg:chunk><dg:chunk structure="div">Intermittent <dgm:Condition>chills </dgm:Condition>with decreased appetite. No fevers, night sweats or weight loss. </dg:chunk></dg:chunk><docset:Eyes-section><dg:chunk structure="h1">

              Eyes: </dg:chunk><docset:Eyes structure="div">No vision changes. ENT: No URI symptoms, mouth <dgm:Condition>ulcers </dgm:Condition>or <dgm:Condition>dysphagia</dgm:Condition>. </docset:Eyes></docset:Eyes-section><docset:SkinJaundiceAndScalySilverNonpruriticRashonRightFlexorSurfaceofElbow><dg:chunk structure="h1">

              Skin: <dgm:Condition>Jaundice </dgm:Condition>and scaly silver nonpruritic rash on right flexor surface of elbow. <dg:chunk>Cardiovascular: Mild SOB</dg:chunk>. No <dgm:Condition>chest pain</dgm:Condition>, DOB or <dgm:Condition>edema</dgm:Condition>. Pulmonary: </dg:chunk><docset:SkinJaundiceAndScalySilverNonpruriticRashonRightFlexorSurfaceofElbow structure="div">No <dgm:Condition>cough </dgm:Condition>(dry or productive), colored sputum, or wheeze. Endocrine: No <dgm:Condition>polyuria</dgm:Condition>, <dgm:Condition>polydipsia</dgm:Condition>, skin /hair changes, heat/cold intolerance. GI: No N/V/C/D, BRBPR, GER, abd pain or bowel changes. GU: No frequency, urgency, <dgm:Condition>dysuria</dgm:Condition>, or <dgm:Condition>hematuria</dgm:Condition>. MSK: See HPI. Intermittent left hand pain. Neurologic: No weakness or numbness. Psychology: No depression, <dgm:Condition>anxiety</dgm:Condition>, or <dgm:Condition>insomnia</dgm:Condition>. Heme/Lymph: Transfusion in July (<docset:TransfusionUnits>3U </docset:TransfusionUnits>PRBCs) </docset:SkinJaundiceAndScalySilverNonpruriticRashonRightFlexorSurfaceofElbow></docset:SkinJaundiceAndScalySilverNonpruriticRashonRightFlexorSurfaceofElbow><docset:PhysicalExamination-section><dg:chunk structure="h1">

              <dg:chunk>Physical <dgm:_testRef>Examination </dgm:_testRef></dg:chunk></dg:chunk><docset:VS-section structure="div"><dg:chunk structure="h1">

              VS: </dg:chunk><docset:VS structure="div"><dg:chunk structure="h1">T: </dg:chunk><dg:chunk structure="div"><docset:BloodPressure>36.3</docset:BloodPressure>; HR: <docset:HeartRate>96</docset:HeartRate>; RR: <docset:PhysicalExamFindings>16</docset:PhysicalExamFindings>; BP: <docset:BloodPressure>108/70</docset:BloodPressure>; O2sat: <docset:OxygenSaturation>89% </docset:OxygenSaturation>RA (h/o upper <dg:chunk>80s</dg:chunk>-low <dg:chunk>90s</dg:chunk>) General: Patient lying in bed in obvious discomfort but NAD. Thin appearance. Eyes: <docset:EyeExam>PERRL</docset:EyeExam>, <docset:EyeMovement>EOMI</docset:EyeMovement>. Significant scleral icterus. ENT: No nasal d/c. <docset:NeckExam>MMM</docset:NeckExam>. Oropharynx clear with no <dgm:Condition>lesions</dgm:Condition>/<dgm:Condition>erythema</dgm:Condition>. Neck: Supple with no LAD or masses. </dg:chunk></docset:VS></docset:VS-section></docset:PhysicalExamination-section><docset:LymphNodes-section><dg:chunk structure="h1">

              <dg:chunk>Lymph Nodes</dg:chunk>: </dg:chunk><docset:LymphNodes structure="div">No cervical or inguinal LAD. <dg:chunk>Cardiovascular: RRR</dg:chunk>. Prominent heart sounds, <docset:HeartSounds>S1 </docset:HeartSounds>and <docset:HeartSounds>S2 </docset:HeartSounds>normal, no m/g/r. Pulses <docset:CardiovascularExam>2</docset:CardiovascularExam>+ equal on both sides. </docset:LymphNodes></docset:LymphNodes-section><docset:Lungs-section><dg:chunk structure="h1">

              Lungs: </dg:chunk><docset:Lungs structure="div">Diffusely decreased breath sounds bilateral. No crackles/rhonchi/wheezes. Good air movement. </docset:Lungs></docset:Lungs-section><docset:Skin-section><dg:chunk structure="h1">

              Skin: </dg:chunk><docset:Skin structure="div">Silver scaly rash on flexor surface of right elbow. Psychiatry: Alert and oriented to person, place, and time Abdomen: Normoactive bowel sounds. Abdomen muscular and tense, NT, ND. Liver palpable <docset:PhysicalExamFindings>1</docset:PhysicalExamFindings>-<docset:AbdominalExam>2 </docset:AbdominalExam>cm below costal margin. Difficult to palpate spleen due to rigidity of abdomen. No rebound or guarding. </docset:Skin></docset:Skin-section><docset:ExtremetiesNoBilateralCyanosisClubbingOrEdemaNoPetechiaeCapillaryRefil><dg:chunk structure="h1">

              Extremeties: No bilateral <dgm:Condition>cyanosis</dgm:Condition>, clubbing or <dgm:Condition>edema</dgm:Condition>. No petechiae. Capillary refill <docset:CapillaryRefill>&lt;3 sec</docset:CapillaryRefill>. MSK: Right knee mild swelling and small effusion. No <dgm:Condition>erythema</dgm:Condition>. Not tender to <dgm:MedicalTest>palpation </dgm:MedicalTest>but painful upon full extension of knee. Left knee exhibited no signficant swelling or tenderness. Full ROM of knees bilaterally. Neurological: </dg:chunk><docset:ExtremetiesNoBilateralCyanosisClubbingOrEdemaNoPetechiaeCapillaryRefil structure="div">Cranial nerves II-<docset:CerebellarFunction>XII </docset:CerebellarFunction>grossly intact, normal sensation throughout, normal cerebellar function. DTR 2+ symmetrical. </docset:ExtremetiesNoBilateralCyanosisClubbingOrEdemaNoPetechiaeCapillaryRefil></docset:ExtremetiesNoBilateralCyanosisClubbingOrEdemaNoPetechiaeCapillaryRefil><docset:PertinentDiagnosticTests-section><dg:chunk structure="h1">

              <dg:chunk>Pertinent Diagnostic Tests </dg:chunk></dg:chunk><docset:PertinentDiagnosticTests structure="div">

              <dgm:MedicalTest>CBC </dgm:MedicalTest>pending. Chem10 WNL (see WebCIS). </docset:PertinentDiagnosticTests></docset:PertinentDiagnosticTests-section><docset:AssessmentAndPlan-section><dg:chunk structure="h1">

              Assessment and Plan </dg:chunk><docset:AssessmentAndPlan structure="div"><dg:chunk><docset:PatientPresentation structure="p">

              <docset:Age>24 </docset:Age>yo African-American man with h/o of sickle cell disease and hypoxia who presents to the ED with bilateral knee pain and minor right knee effusion. DDx includes vasoocclusive disease </docset:PatientPresentation><dg:chunk structure="p">

              (VOD), periarticular infarct, septic <dgm:Condition>arthritis </dgm:Condition><dgm:Condition>gout</dgm:Condition>. </dg:chunk></dg:chunk><dg:chunk><docset:KNEEPAINEFFUSION-section><dg:chunk structure="h1">

              <docset:KneePain>KNEE </docset:KneePain>PAIN/EFFUSION: </dg:chunk><docset:KNEEPAINEFFUSION structure="div">Unclear etiology with DDx including VOD, periarticular infarct, septic <dgm:Condition>arthritis</dgm:Condition>, or <dgm:Condition>gout</dgm:Condition>. VOD or periarticular infarct most likely given afebrile presentation. Radiographs are usually of low yield and therefore not warranted. Consider NSAID treatment with <dgm:Medication>morphine </dgm:Medication>for breakthrough pain. If patient spikes fever or <dgm:MedicalTest>CBC </dgm:MedicalTest>demonstrates marked <dgm:Condition>leukocytosis</dgm:Condition>, will obtain blood cultures and begin empirical Abx treatment with coverage for Staph and <dgm:Bacterium>Salmonella</dgm:Bacterium>. </docset:KNEEPAINEFFUSION></docset:KNEEPAINEFFUSION-section><docset:SICKLECELLDISEASE-section><dg:chunk structure="h1">

              <dg:chunk>SICKLE CELL DISEASE</dg:chunk>: </dg:chunk><docset:SICKLECELLDISEASE structure="div"><docset:MonitoringRequirements structure="p">Previously asymptomatic. Monitor closely for acute chest <dgm:Condition>syndrome </dgm:Condition>(CXR pending), <dgm:Condition>splenic sequestration </dgm:Condition>or aplastic crisis. </docset:MonitoringRequirements><dg:chunk><docset:HYPOXIA-section><dg:chunk structure="h1">

              HYPOXIA: </dg:chunk><docset:HYPOXIA structure="div">Patient normal <docset:OxygenTreatment>O2 </docset:OxygenTreatment>sats are <docset:NormalO2SatsRange>80s-90s </docset:NormalO2SatsRange>per Clinic note. Will obtain CXR to r/o new infiltrates. Consider O2 treatment if patient becomes symptomatic. </docset:HYPOXIA></docset:HYPOXIA-section><docset:DISPO-section><dg:chunk structure="h1">

              DISPO: </dg:chunk><docset:DISPO structure="div">d/c tomorrow if pain improves. </docset:DISPO></docset:DISPO-section></dg:chunk></docset:SICKLECELLDISEASE></docset:SICKLECELLDISEASE-section></dg:chunk></docset:AssessmentAndPlan></docset:AssessmentAndPlan-section><docset:Discussion-section><dg:chunk structure="h1">

              Discussion </dg:chunk><docset:Discussion structure="div"><docset:SickleCellDisease structure="p">

              Sickle cell disease (SCD) is an autosomal recessive disorder that involves a point mutation in the β-globin gene (Glu6Val). The mutation alters the structure of the hemoglobin molecule (HbS), causing aggregation of hemoglobin under conditions of deoxygenation. Aggregation and polymerization of <docset:HemoglobinS>HbS </docset:HemoglobinS>distorts erythrocyte structure into a “sickle” shape. Sickled cells have a reduced lifespan, resulting in chronic hemolytic <dgm:Condition>anemia</dgm:Condition>. Sickled cells also have an increased propensity to attach to the endothelium of postcapillary venules and cause <dgm:Condition>vascular <dgm:Condition>occlusion</dgm:Condition></dgm:Condition>. The vascular obstruction and resulting <dgm:Condition>ischemia </dgm:Condition>are responsible for the recurrent episodes of acute pain that are characteristic of sickle cell disease. More life-threatening complications of sickle cell disease include acute chest <dgm:Condition>syndrome</dgm:Condition>, <dgm:Condition>splenic sequestration </dgm:Condition>and aplastic <dgm:Condition>anemia </dgm:Condition>(<docset:SickleCellDisease>1</docset:SickleCellDisease>). </docset:SickleCellDisease><docset:TreatmentOptions structure="p">

              The severe knee pain in the patient is likely secondary a vasoocclusive event leading to periarticular <dgm:Condition>infarction</dgm:Condition>. Microvascular <dgm:Condition>occlusion </dgm:Condition>most often occurs within bone marrow, but can arise in practically any anatomical location. The pathophysiology involves the attachment of sickle cells to endothelium, resulting in the formation of heterocellular aggregates composed of sickle cells, leukocytes and platelets. <dgm:Condition>Vascular <dgm:Condition>occlusion </dgm:Condition></dgm:Condition>by the heterocellular aggregates results in <dgm:Condition>infarction </dgm:Condition>and the release of inflammatory mediators, which induce pain through activation of nociceptive afferent nerve fibers (<docset:TreatmentPlan>2</docset:TreatmentPlan>). Management of painful vasoocclusive crises involves hydration, warm packs on the affected areas, and a combination of opioid or nonopioid analgesics and NSAIDs. Painful crises that result in a visit to the ER should be treated promptly with high-dose <dgm:Medication>morphine</dgm:Medication>, as early pain management can decrease the likelihood of costly hospitalization (<docset:TreatmentPlan>3</docset:TreatmentPlan>). For patients with recurrent vasooclusive events, treatment with hydroxurea has been shown to decrease the rate of pain crises (<docset:TreatmentPlan>4</docset:TreatmentPlan>). <dgm:Medication>Hydroxyurea </dgm:Medication>has also been shown to cause a modest decrease in mortality for patients with SCD (5). </docset:TreatmentOptions></docset:Discussion></docset:Discussion-section><docset:ThePatientAlsoPresentedwithChronicHypoxiaAndDyspneaWhichAreFrequentM><dg:chunk structure="h1">

              The patient also presented with chronic hypoxia and dyspnea, which are frequent manifestations of chronic lung disease associated with SCD. SCD is <dgc:Frequency>frequently </dgc:Frequency>associated with pulmonary hyperreactivity, restrict lung disease and pulmonary <dgm:Condition>hypertension </dgm:Condition>(<docset:TreatmentOptions>6</docset:TreatmentOptions>). A recent <dgm:_testRef>study </dgm:_testRef>found that approximately <docset:PulmonaryFunctionTestResults>90% </docset:PulmonaryFunctionTestResults>adult patients with <docset:PulmonaryComplications>SCD </docset:PulmonaryComplications>exhibited abnormal PFT functions, including decreased total lung capacities and diffusion capacity for carbon monoxide (7). Unfortunately, pulmonary complications of SCD account for <docset:PulmonaryComplicationsMortality>20-30% </docset:PulmonaryComplicationsMortality>of the mortality in patients (<docset:TreatmentOptions>5</docset:TreatmentOptions>). Investigational treatments for the pulmonary complications of SCD include inhalational <dgm:Medication>nitric oxide </dgm:Medication>(NO) and its precursor oral L-arginine. NO induces pulmonary vasodilation, thus alleviating pulmonary <dgm:Condition>hypertension</dgm:Condition>. NO also acts as inhibits expression of cell adhesion molecules involved with binding of sickle cells to endothelium and decreases production of proinflammatory mediators. While transgenic mouse models have suggested a beneficial role of NO and L-arginine for pulmonary complications of SCD, clinical trials are currently lacking (<docset:TreatmentOptions>2</docset:TreatmentOptions>). 

              References </dg:chunk><docset:ThePatientAlsoPresentedwithChronicHypoxiaAndDyspneaWhichAreFrequentM structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 879.2; width: 1945.8; height: 1258.3; page: 4;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 879.2; width: 1858.3; height: 108.3; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 879.2; width: 37.5; height: 50.0; page: 4;}; ">

              1. </dg:chunk><docset:HematologyTextbook structure="p"><docset:Author>Hoffman, R. </docset:Author>Hematology: basic principles and practice. 4th edition, pp. xxix, <docset:NumberofPages>2821 </docset:NumberofPages>p. Philadelphia, Pa.: <docset:Publisher>Churchill </docset:Publisher><docset:Publisher>Livingstone, </docset:Publisher><docset:PublicationDate>2005</docset:PublicationDate>. </docset:HematologyTextbook></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 991.7; width: 1766.7; height: 54.2; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 995.8; width: 37.5; height: 50.0; page: 4;}; ">

              2. </dg:chunk><dg:chunk structure="p"><docset:Author>Stuart, M. J. </docset:Author>and <docset:Author>Nagel, R. L. </docset:Author>Sickle-cell disease. Lancet, <docset:LancetIssue>364</docset:LancetIssue>: <docset:ArticleRange><docset:ArticleStartPage>1343</docset:ArticleStartPage>-<docset:EndofArticle>1360</docset:EndofArticle></docset:ArticleRange>, <docset:PublicationDate>2004</docset:PublicationDate>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1050.0; width: 1866.7; height: 166.7; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1050.0; width: 37.5; height: 50.0; page: 4;}; ">

              3. </dg:chunk><docset:SickleCellAnemiaDayHospital structure="p"><docset:Author>Benjamin, L. J., </docset:Author><docset:Author>Swinson, G. I.</docset:Author>, and <docset:Author>Nagel, R. L. </docset:Author><docset:SickleCellAnemiaDayHospital>Sickle </docset:SickleCellAnemiaDayHospital>cell <dgm:Condition>anemia </dgm:Condition>day hospital: an approach for the management of uncomplicated painful crises. Blood, <docset:Publication>95</docset:Publication>: <docset:ArticleText><docset:ArticleTitle>1130</docset:ArticleTitle>-<docset:References>1136</docset:References></docset:ArticleText>, <docset:PublicationDate>2000</docset:PublicationDate>. </docset:SickleCellAnemiaDayHospital></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1225.0; width: 1858.3; height: 220.8; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1225.0; width: 37.5; height: 50.0; page: 4;}; ">

              4. </dg:chunk><dg:chunk><docset:StudyAuthor>Charache, S.</docset:StudyAuthor>, <docset:StudyInvestigators>Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B.</docset:StudyInvestigators>, <docset:HydroxyureaStudy>Eckert, S. V., McMahon, R. P.</docset:HydroxyureaStudy>, and <docset:HydroxyureaStudy>Bonds, D. R. </docset:HydroxyureaStudy>Effect of <dgm:Medication>hydroxyurea </dgm:Medication>on the frequency of painful crises in sickle cell <dgm:Condition>anemia</dgm:Condition>. Investigators of the <dg:chunk>Multicenter <dgm:_testRef>Study </dgm:_testRef></dg:chunk>of <dgm:Medication>Hydroxyurea </dgm:Medication>in <dg:chunk>Sickle Cell <dgm:Condition>Anemia</dgm:Condition></dg:chunk>. <dg:chunk>N Engl J Med</dg:chunk>, <docset:JournalIssue>332</docset:JournalIssue>: <docset:StudyResults><docset:StudyPublication>1317</docset:StudyPublication>-<docset:StudyEndDate>1322</docset:StudyEndDate></docset:StudyResults>, <docset:PublicationDate>1995</docset:PublicationDate>. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 1454.2; width: 1758.3; height: 337.5; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1454.2; width: 37.5; height: 50.0; page: 4;}; ">

              5. </dg:chunk><docset:HydroxyureaStudy structure="p"><docset:Authors>Steinberg, M. H., Barton, F., Castro, O.</docset:Authors>, <docset:AuthorList>Pegelow, C. H.</docset:AuthorList>, <docset:StudyAuthor>Ballas, S. K.</docset:StudyAuthor>, <docset:StudyAuthor>Kutlar, A.</docset:StudyAuthor>, <docset:StudyAuthor>Orringer, E.</docset:StudyAuthor>, <docset:StudyAuthor>Bellevue, R., </docset:StudyAuthor><docset:StudyReference>Olivieri, N.</docset:StudyReference>, <docset:Author>Eckman, </docset:Author><docset:Journal>J.</docset:Journal>, <docset:StudyAuthors>Varma, M., Ramirez, G.</docset:StudyAuthors>, <docset:StudyAuthor>Adler</docset:StudyAuthor><docset:StudyReference>, B.</docset:StudyReference>, <docset:Authors>Smith</docset:Authors><docset:StudyAuthors>, W.</docset:StudyAuthors>, <docset:StudyReference>Carlos, T.</docset:StudyReference>, <docset:StudyAuthor>Ataga, K.</docset:StudyAuthor>, <docset:StudyAuthor>DeCastro, L.</docset:StudyAuthor>, <docset:StudyAuthor>Bigelow, C.</docset:StudyAuthor>, <docset:StudyResults>Saunthararajah, Y.</docset:StudyResults>, <docset:StudyReference>Telfer, M.</docset:StudyReference>, <docset:StudyAuthor>Vichinsky</docset:StudyAuthor>, <docset:StudyDesign>E.</docset:StudyDesign>, <docset:StudyAuthor>Claster, S.</docset:StudyAuthor>, <docset:StudyAuthors>Shurin, S., Bridges, K.</docset:StudyAuthors>, <docset:StudyReference>Waclawiw, M.</docset:StudyReference>, <docset:AuthorList>Bonds, D.</docset:AuthorList>, and <docset:StudyAuthor>Terrin, M. </docset:StudyAuthor>Effect of <dgm:Medication>hydroxyurea </dgm:Medication>on mortality and morbidity in adult sickle cell <dgm:Condition>anemia</dgm:Condition>: risks and benefits up to <docset:TreatmentDuration>9 years </docset:TreatmentDuration>of treatment. Jama, <docset:JournalVolume>289</docset:JournalVolume>: <docset:ArticleText><docset:ArticleTitle>1645</docset:ArticleTitle>-<docset:EndofStudy>1651</docset:EndofStudy></docset:ArticleText>, <docset:PublicationDate>2003</docset:PublicationDate>. </docset:HydroxyureaStudy></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1800.0; width: 1941.7; height: 162.5; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1800.0; width: 37.5; height: 50.0; page: 4;}; ">

              6. </dg:chunk><docset:SickleCellChronicLungDisease structure="p"><docset:Author>Powars, D.</docset:Author>, <docset:SickleCellChronicLungDisease>Weidman, J. A.</docset:SickleCellChronicLungDisease>, <docset:PriorMorbidityandPulmonaryFailure>Odom-Maryon, T., Niland, J. C.</docset:PriorMorbidityandPulmonaryFailure>, and <docset:SickleCellChronicLungDisease>Johnson, C. </docset:SickleCellChronicLungDisease>Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. <docset:SickleCellChronicLungDisease>Medicine </docset:SickleCellChronicLungDisease>(Baltimore), <docset:Reference>67</docset:Reference>: <docset:Reference>66</docset:Reference><docset:SickleCellChronicLungDisease>-</docset:SickleCellChronicLungDisease><docset:References>76</docset:References>, <docset:PublicationDate>1988</docset:PublicationDate>. </docset:SickleCellChronicLungDisease></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1972.0; width: 1945.8; height: 165.5; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1970.8; width: 37.5; height: 50.0; page: 4;}; ">

              7. </dg:chunk><docset:PulmonaryFunctioninSickleCellAnemia structure="p"><docset:Author>Klings, E. S.</docset:Author>, <docset:Author>Wyszynski, <docset:References>D. </docset:References></docset:Author><docset:References>F.</docset:References>, <docset:Author>Nolan, V. G.</docset:Author>, and <docset:Author>Steinberg</docset:Author><docset:Author>, M. H. </docset:Author>Abnormal pulmonary function in adults with sickle cell <dgm:Condition>anemia</dgm:Condition>. <docset:ArticleReference>Am J Respir </docset:ArticleReference>Crit Care Med, <docset:JournalVolume>173</docset:JournalVolume>: <docset:ArticleRange><docset:ArticleStartPage>1264</docset:ArticleStartPage>-<docset:EndofArticle>1269</docset:EndofArticle></docset:ArticleRange>, <docset:PublicationDate>2006</docset:PublicationDate>.</docset:PulmonaryFunctioninSickleCellAnemia></dg:chunk></docset:ThePatientAlsoPresentedwithChronicHypoxiaAndDyspneaWhichAreFrequentM></docset:ThePatientAlsoPresentedwithChronicHypoxiaAndDyspneaWhichAreFrequentM></dg:chunk>